loading
Foghorn Therapeutics Inc stock is traded at $6.19, with a volume of 102.16K. It is down -4.33% in the last 24 hours and up +27.10% over the past month. Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$6.47
Open:
$6.42
24h Volume:
102.16K
Relative Volume:
0.80
Market Cap:
$345.04M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-2.6453
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
+1.48%
1M Performance:
+27.10%
6M Performance:
+52.46%
1Y Performance:
-0.96%
1-Day Range:
Value
$6.11
$6.46
1-Week Range:
Value
$5.9401
$6.49
52-Week Range:
Value
$2.9448
$10.25

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name
Name
Foghorn Therapeutics Inc
Name
Phone
617-586-3100
Name
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Name
Employee
112
Name
Twitter
Name
Next Earnings Date
2025-03-07
Name
Latest SEC Filings
Name
FHTX's Discussions on Twitter

Compare FHTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
FHTX
Foghorn Therapeutics Inc
6.19 353.40M 34.16M -98.43M -119.33M -2.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-23-25 Initiated Citizens JMP Mkt Outperform
Jan-30-25 Initiated B. Riley Securities Buy
Sep-03-24 Initiated Jefferies Buy
Aug-19-24 Initiated Evercore ISI Outperform
Mar-28-23 Initiated BofA Securities Buy
Jan-05-23 Initiated BMO Capital Markets Outperform
Nov-22-21 Initiated H.C. Wainwright Buy
Nov-17-20 Initiated Cowen Outperform
Nov-17-20 Initiated Goldman Buy
Nov-17-20 Initiated Morgan Stanley Overweight
Nov-17-20 Initiated Wedbush Outperform
View All

Foghorn Therapeutics Inc Stock (FHTX) Latest News

pulisher
Jul 24, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jul 24, 2025
pulisher
Jul 23, 2025

Foghorn Therapeutics Inc. Stock Analysis and ForecastOutstanding risk-reward balance - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Trading (FHTX) With Integrated Risk Controls - news.stocktradersdaily.com

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Foghorn Therapeutics Inc. stockAccelerated capital growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Foghorn Therapeutics Inc. stock pricePhenomenal capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Foghorn Therapeutics Inc. a good long term investmentFree Stock Market Trend Analysis - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 0.5% – What’s Next? - Defense World

Jul 22, 2025
pulisher
Jul 21, 2025

Why Foghorn Therapeutics Inc. stock attracts strong analyst attentionTriple Return With Stability - Newser

Jul 21, 2025
pulisher
Jul 19, 2025

SAIL Stock Analysis and ForecastFree Trading Psychology Coaching - Jammu Links News

Jul 19, 2025
pulisher
Jul 19, 2025

What analysts say about Leonardo DRS Inc. stockMarket-beating performance - Jammu Links News

Jul 19, 2025
pulisher
Jul 15, 2025

What makes Foghorn Therapeutics Inc. stock price move sharplyHigh Potential Safe Trades - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Foghorn Therapeutics Inc. stock performs during market volatilityConsistent Win Signals - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

(FHTX) Trading Report - news.stocktradersdaily.com

Jul 12, 2025
pulisher
Jul 10, 2025

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares May Have Run Too Fast Too Soon - simplywall.st

Jul 10, 2025
pulisher
Jul 02, 2025

(FHTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Jul 02, 2025
pulisher
Jul 02, 2025

112-employee biotech leaves Cambridge HQ for Watertown - The Business Journals

Jul 02, 2025
pulisher
Jul 01, 2025

Foghorn Therapeutics Signs New Lease Agreement - TipRanks

Jul 01, 2025
pulisher
Jun 29, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Jun 29, 2025
pulisher
Jun 25, 2025

Exchange Traded Concepts LLC Grows Holdings in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Jun 25, 2025
pulisher
Jun 21, 2025

When the Price of (FHTX) Talks, People Listen - news.stocktradersdaily.com

Jun 21, 2025
pulisher
Jun 17, 2025

Foghorn Therapeutics Holds Successful Annual Meeting - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Bank of America Corp DE Has $149,000 Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Jun 17, 2025
pulisher
Jun 13, 2025

Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, And Clinical Trial Progress Assessment By Delveinsight Oncotherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - MENAFN.com

Jun 13, 2025
pulisher
Jun 11, 2025

Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - Barchart.com

Jun 11, 2025
pulisher
Jun 11, 2025

Trend Tracker for (FHTX) - news.stocktradersdaily.com

Jun 11, 2025
pulisher
Jun 10, 2025

Millennium Management LLC Raises Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Jun 10, 2025
pulisher
Jun 08, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Acquired by Wellington Management Group LLP - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives $12.13 Consensus Target Price from Analysts - Defense World

Jun 07, 2025
pulisher
Jun 03, 2025

BNP Paribas Financial Markets Makes New $61,000 Investment in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Jun 03, 2025
pulisher
May 29, 2025

Northern Trust Corp Purchases 2,873 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 29, 2025
pulisher
May 26, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Position Increased by D. E. Shaw & Co. Inc. - Defense World

May 26, 2025
pulisher
May 26, 2025

Lazard Asset Management LLC Acquires New Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 26, 2025

Foghorn Therapeutics Inc Stock (FHTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Cap:     |  Volume (24h):